CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions

Inclusion Criteria:

• Subjects presenting with claudication or CLI by Rutherford Clinical Category 2, 3, 4, 5, or 6 of the target limbs

• Subject is a suitable candidate for angiography and endovascular intervention perthe latest clinical guidelines

• Patient is scheduled to undergo treatment with Shockwave Intravascular Lithotripsy (IVL) technology followed by standard of care treatment with DCB, BMS, DES at thephysician's discretion.

Angiographic Inclusion Criteria

• Target lesion that is located in a native, de novo common femoral artery

• Target lesion reference vessel diameter is between 4.0mm and 7.0mm by visualestimate.

• Target lesion is ≥70% stenosis by investigator via visual estimate.

• Target lesion length is ≤50mm for lesions 70-99% stenosed. Target lesion can be allor part of the 50mm treated zone.

• Chronic total occlusion, lesion length is ≤50mm of the total ≤50 mm target lesion.

• Calcification is at least moderate defined as presence of fluoroscopic evidence ofcalcification: 1) on parallel sides of the vessel and 2) extending > 50% the lengthof the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm iflesion is <50mm in length.

Exclusion Criteria:

• Subjects with any medical condition that would make him/her an inappropriatecandidate for treatment with Shockwave Medical Peripheral Lithoplasty® System as perInstructions for Use (IFU) or investigator's opinion.

• Subject is already enrolled in other investigational (interventional) studies thatwould interfere with study endpoints.

• Cognitive impairment as documented in medical records

• Not speaking English or Spanish

• Currently a prisoner

• Pregnancy or nursing

• Estimated survival less than 12 months at the time of screening

• Prior history of CFA endarterectomy